ZES
MCID: ZLL002
MIFTS: 53

Zollinger-Ellison Syndrome (ZES) malady

Categories: Rare diseases, Gastrointestinal diseases, Endocrine diseases

Aliases & Classifications for Zollinger-Ellison Syndrome

Aliases & Descriptions for Zollinger-Ellison Syndrome:

Name: Zollinger-Ellison Syndrome 12 50 56 29 52 42 14 69
Gastrinoma 50 56 69
Pancreatic Ulcerogenic Tumor Syndrome 50
Z E Syndrome 50
Zes 50

Characteristics:

Orphanet epidemiological data:

56
zollinger-ellison syndrome
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe),1-9/1000000 (Worldwide); Age of onset: Adult; Age of death: normal life expectancy;

Classifications:



External Ids:

Disease Ontology 12 DOID:0050782
ICD10 33 E16.4
MeSH 42 D015043
NCIt 47 C3453
Orphanet 56 ORPHA913
MESH via Orphanet 43 D015043 D015408
ICD10 via Orphanet 34 E16.4 C25.4 D37.7
UMLS via Orphanet 70 C0017150 C0043515
UMLS 69 C0043515

Summaries for Zollinger-Ellison Syndrome

NIH Rare Diseases : 50 zollinger-ellison syndrome (zes) is a condition in which tumors called gastrinomas in the pancreas and duodenum (part of the small intestine) cause high levels of the hormone gastrin in the blood. high levels of gastrin then cause production of too much stomach acid. signs and symptoms may include abdominal pain, peptic ulcers, vomiting blood, and diarrhea. the tumors are sometimes cancerous and may spread to other areas of the body. in most cases, the cause of zes is unknown. however, about 25-30% of gastrinomas are caused by an inherited condition called multiple endocrine neoplasia type 1 (men1). treatment for zes may include medication to reduce the production of stomach acid, and surgery for peptic ulcers or to remove tumors. last updated: 1/14/2014

MalaCards based summary : Zollinger-Ellison Syndrome, also known as gastrinoma, is related to pheochromocytoma and multiple endocrine neoplasia 1, and has symptoms including nausea, weight loss and jaundice. An important gene associated with Zollinger-Ellison Syndrome is SCT (Secretin), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Lansoprazole and Pantoprazole have been mentioned in the context of this disorder. Affiliated tissues include pancreas, small intestine and pituitary.

Disease Ontology : 12 A syndrome that is haracterized by the development of a one or more tumors (gastrinoma) in the pancreas, duodenum, or both that secrete excessive levels of gastrin, a hormone that stimulates production of acid by the stomach.

Wikipedia : 71 Zollinger–Ellison syndrome (ZES) is a disease in which tumors cause the stomach to produce too much... more...

Related Diseases for Zollinger-Ellison Syndrome

Diseases related to Zollinger-Ellison Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 145)
id Related Disease Score Top Affiliating Genes
1 pheochromocytoma 29.7 CHGA MEN1 SST
2 multiple endocrine neoplasia 1 11.2
3 gastrinoma 10.8
4 multiple endocrine neoplasia 10.7
5 duodenitis 10.6
6 pancreatitis 10.5
7 esophagitis 10.4
8 duodenal ulcer 10.3
9 gastritis 10.3
10 cystadenocarcinoma 10.3
11 hyperparathyroidism 10.3
12 hepatitis 10.3
13 islet cell tumor 10.3
14 cystadenoma 10.3
15 post-vaccinal encephalitis 10.3 GAST SCT
16 syphilitic encephalitis 10.2 GAST SCT
17 duodenal gastrinoma 10.2
18 steatorrhea 10.2
19 cushing's syndrome 10.2
20 diarrhea 10.2
21 nutritional optic neuropathy 10.2 GAST SST
22 cherubism 10.2 GAST SST
23 breast cystic hypersecretory carcinoma 10.2 GAST HRH2
24 ovarian mucinous neoplasm 10.2 GAST HRH2
25 myocardial stunning 10.2 GAST SST
26 color blindness 10.2 GAST SST
27 tooth erosion 10.2 SCT SST
28 autoimmune pancreatitis 10.2 CHGA GAST
29 nasal cavity cancer 10.2 GAST HRH2
30 peptic ulcer disease 10.2
31 mucinous cystadenocarcinoma 10.2
32 carcinoid syndrome 10.2
33 short bowel syndrome 10.1 SCT SST
34 gastric duplication cysts 10.1 CHGA GAST
35 granulocytopenia 10.1 CHGA GAST
36 scleral staphyloma 10.1 HRH2 SST
37 acinar cell cystadenocarcinoma 10.1 CHGA GAST
38 pemphigus foliaceus 10.1 MEN1 SST
39 uterine ligament cancer 10.1 MEN1 SST
40 thymus small cell carcinoma 10.1 CHGA GRP
41 early-onset parkinson disease 10.1 MEN1 SST
42 childhood central nervous system mixed germ cell tumor 10.1 GAST HRH2 SCT
43 pulmonary neuroendocrine tumor 10.1 MEN1 SST
44 neuroretinitis 10.1 MEN1 SST
45 adult ependymoblastoma 10.1 CHGA MEN1
46 oculocutaneous albinism 10.1 CHGA SST
47 breast secretory carcinoma 10.1 CHGA SST
48 lipid-rich carcinoma 10.1 CHGA GRP
49 insulinoma 10.1
50 acromegaly 10.1

Graphical network of the top 20 diseases related to Zollinger-Ellison Syndrome:



Diseases related to Zollinger-Ellison Syndrome

Symptoms & Phenotypes for Zollinger-Ellison Syndrome

Human phenotypes related to Zollinger-Ellison Syndrome:

56 32 (show all 35)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 nausea 56 32 Very frequent (99-80%) HP:0002018
2 weight loss 56 32 Frequent (79-30%) HP:0001824
3 jaundice 56 32 Occasional (29-5%) HP:0000952
4 multiple lipomas 56 32 Occasional (29-5%) HP:0001012
5 intestinal obstruction 56 32 Occasional (29-5%) HP:0005214
6 hyperparathyroidism 56 32 Occasional (29-5%) HP:0000843
7 extrahepatic cholestasis 56 32 Occasional (29-5%) HP:0012334
8 glucagonoma 56 32 Occasional (29-5%) HP:0030404
9 increased glucagon level 56 32 Occasional (29-5%) HP:0030688
10 adrenocortical carcinoma 56 32 Very rare (<4-1%) HP:0006744
11 hypercalcemia 56 32 Occasional (29-5%) HP:0003072
12 elevated circulating parathyroid hormone level 56 32 Occasional (29-5%) HP:0003165
13 parathyroid hyperplasia 56 32 Occasional (29-5%) HP:0008208
14 growth hormone excess 56 32 Occasional (29-5%) HP:0000845
15 thyroid adenoma 56 32 Occasional (29-5%) HP:0000854
16 zollinger-ellison syndrome 56 32 Obligate (100%) HP:0002044
17 episodic abdominal pain 56 32 Very frequent (99-80%) HP:0002574
18 peptic ulcer 56 32 Very frequent (99-80%) HP:0004398
19 pituitary prolactin cell adenoma 56 32 Occasional (29-5%) HP:0006767
20 adrenocortical adenoma 56 32 Occasional (29-5%) HP:0008256
21 pituitary growth hormone cell adenoma 56 32 Occasional (29-5%) HP:0011760
22 pituitary null cell adenoma 56 32 Occasional (29-5%) HP:0011761
23 esophagitis 56 32 Very frequent (99-80%) HP:0100633
24 pituitary corticotropic cell adenoma 56 32 Occasional (29-5%) HP:0008291
25 erythema 56 32 Occasional (29-5%) HP:0010783
26 increased urinary cortisol level 56 32 Occasional (29-5%) HP:0012030
27 hematochezia 56 32 Occasional (29-5%) HP:0002573
28 lipoma 56 32 Occasional (29-5%) HP:0012032
29 duodenal ulcer 56 32 Very frequent (99-80%) HP:0002588
30 diarrhea 56 Very frequent (99-80%)
31 neuroendocrine neoplasm 56 Obligate (100%)
32 gastrointestinal hemorrhage 56 Occasional (29-5%)
33 pituitary adenoma 56 Occasional (29-5%)
34 hypercortisolism 56 Occasional (29-5%)
35 increased circulating cortisol level 32 HP:0003118

UMLS symptoms related to Zollinger-Ellison Syndrome:


dyspepsia

Drugs & Therapeutics for Zollinger-Ellison Syndrome

Drugs for Zollinger-Ellison Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 136)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lansoprazole Approved, Investigational Phase 4,Phase 1 103577-45-3 3883
2
Pantoprazole Approved Phase 4,Phase 2 102625-70-7 4679
3
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
4 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
5 pancreatic polypeptide Phase 4,Phase 2,Phase 3,Phase 1
6 Antacids Phase 4,Phase 3,Phase 2,Phase 1
7 Anti-Ulcer Agents Phase 4,Phase 3,Phase 2,Phase 1
8
Dexlansoprazole Phase 4,Phase 1 138530-94-6, 103577-45-3 9578005
9 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
10
Proton pump inhibitors Phase 4,Phase 3,Phase 2,Phase 1
11
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
12
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
13
Levoleucovorin Approved Phase 2, Phase 3,Phase 1 68538-85-2
14
Oxaliplatin Approved, Investigational Phase 2, Phase 3,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
15
Esomeprazole Approved, Investigational Phase 3,Phase 1 161796-78-7, 119141-88-7 4594 9579578
16
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
17
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
18
leucovorin Approved, Nutraceutical Phase 2, Phase 3, Phase 1 58-05-9 54575, 6560146 143
19 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 1
20 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 1
21 Antimetabolites Phase 2, Phase 3,Phase 1
22 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1
23 Immunosuppressive Agents Phase 2, Phase 3,Phase 1
24 Calcimimetic Agents Phase 3
25 Calcium, Dietary Phase 3,Phase 2,Phase 1
26 Cinacalcet Hydrochloride Phase 3
27 Hormone Antagonists Phase 3,Phase 2,Phase 1
28 Hormones Phase 3,Phase 2,Phase 1
29 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1
30 Adjuvants, Anesthesia Phase 3
31 Analgesics Phase 3
32 Analgesics, Opioid Phase 3
33 Anesthetics Phase 3
34 Anesthetics, General Phase 3
35 Anesthetics, Intravenous Phase 3
36 Central Nervous System Depressants Phase 3
37 Narcotics Phase 3
38 Peripheral Nervous System Agents Phase 3
39 Folate Nutraceutical Phase 2, Phase 3
40 Vitamin B9 Nutraceutical Phase 2, Phase 3
41 Cola Nutraceutical Phase 3,Phase 1
42
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
43
Octreotide Approved, Investigational Phase 2,Phase 1 83150-76-9 383414 6400441
44
Pancrelipase Approved Phase 2,Phase 1 53608-75-6
45
Streptozocin Approved Phase 2 18883-66-4 29327
46
Omeprazole Approved, Investigational, Vet_approved Phase 2,Phase 1 73590-58-6 4594
47
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
48
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
49
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
50
Capecitabine Approved, Investigational Phase 2,Phase 1 154361-50-9 60953

Interventional clinical trials:

(show top 50) (show all 54)
id Name Status NCT ID Phase
1 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376 Phase 4
2 Treatment of Zollinger-Ellison Syndrome With Prevacid Completed NCT00204373 Phase 4
3 A Study of Rabeprazole and Pantoprazole on Stomach Acid and Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease (GERD) and a History of Nighttime Heartburn Completed NCT00237367 Phase 4
4 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3
5 Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome Completed NCT00079833 Phase 3
6 A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases Completed NCT02153398 Phase 3
7 Cinacalcet to Treat Familial Primary Hyperparathyroidism Completed NCT00325104 Phase 3
8 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
9 Interferon and Octreotide to Treat Zollinger-Ellison Syndrome and Advanced Non-B Islet Cell Cancer Completed NCT00001228 Phase 2
10 Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the Pancreas Completed NCT00001165 Phase 2
11 The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid Completed NCT00001191 Phase 2
12 Effect of G17DT in Patients With Stage II/III Colorectal Cancer Completed NCT02518373 Phase 2
13 Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00131911 Phase 2
14 Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00075439 Phase 2
15 PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00017199 Phase 2
16 Capecitabine and Temozolomide for Neuroendocrine Cancers Completed NCT00869050 Phase 2
17 Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00027638 Phase 2
18 Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery Completed NCT00416767 Phase 2
19 AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2
20 Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors Completed NCT00602082 Phase 2
21 EPO906 in Carcinoid and Other Neuroendocrine Tumors Completed NCT00050349 Phase 2
22 Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer Completed NCT00454363 Phase 2
23 Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors Recruiting NCT02259725 Phase 2
24 Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery Active, not recruiting NCT01229943 Phase 2
25 Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01824875 Phase 2
26 Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01525082 Phase 2
27 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Active, not recruiting NCT01010126 Phase 2
28 YF476 and Type II Gastric Carcinoids Enrolling by invitation NCT02454075 Phase 2
29 Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery Terminated NCT02031536 Phase 2
30 Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors Terminated NCT00084461 Phase 2
31 Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer Terminated NCT02273752 Phase 2
32 Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors Terminated NCT00466856 Phase 2
33 Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors Withdrawn NCT02108782 Phase 2
34 Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors Withdrawn NCT00227773 Phase 2
35 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
36 A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants. Completed NCT00942175 Phase 1
37 Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors Completed NCT00049023 Phase 1
38 Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer Completed NCT00006368 Phase 1
39 Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum Completed NCT00005860 Phase 1
40 Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer Completed NCT00005842 Phase 1
41 Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma Completed NCT01204476 Phase 1
42 Laser Tissue Welding - Distal Pancreatectomy Sealing Study Recruiting NCT03147768 Phase 1
43 Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors Active, not recruiting NCT00655655 Phase 1
44 Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Not yet recruiting NCT02831179 Phase 1
45 Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Terminated NCT00002947 Phase 1
46 Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors Unknown status NCT00730483
47 Treatment of Zollinger-Ellison Syndrome Completed NCT00001241
48 Evaluating Pancreatic Tumors in Patients With Zollinger-Ellison Syndrome Completed NCT00001254
49 Nexium Capsules Clinical Experience Investigation Completed NCT01434485
50 Evaluating Patients With Abnormal Levels of Gastric Acid Completed NCT00001240

Search NIH Clinical Center for Zollinger-Ellison Syndrome

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: zollinger-ellison syndrome

Genetic Tests for Zollinger-Ellison Syndrome

Genetic tests related to Zollinger-Ellison Syndrome:

id Genetic test Affiliating Genes
1 Zollinger-Ellison Syndrome 29

Anatomical Context for Zollinger-Ellison Syndrome

MalaCards organs/tissues related to Zollinger-Ellison Syndrome:

39
Pancreas, Small Intestine, Pituitary, Testes, Liver, Thyroid, Lymph Node

Publications for Zollinger-Ellison Syndrome

Articles related to Zollinger-Ellison Syndrome:

(show top 50) (show all 527)
id Title Authors Year
1
A Perplexing Case of Abdominal Pain That Led to the Diagnosis of Zollinger-Ellison Syndrome. ( 28321346 )
2017
2
Zollinger-Ellison Syndrome: A Rare Case of Chronic Diarrhea. ( 28058079 )
2016
3
Zollinger-Ellison syndrome: an unusual case of chronic diarrhoea in a child. ( 28028304 )
2016
4
Assessing for multiple endocrine neoplasia type 1 in patients evaluated for Zollinger-Ellison Syndrome - clues to a safer diagnostic process. ( 28011308 )
2016
5
Zollinger-Ellison Syndrome Associated with von Recklinghausen Disease: Case Report and Literature Review. ( 27292293 )
2016
6
Intraoperative near-infrared fluorescence visualization of theA duodenal gastrinoma in a patient withA Zollinger-Ellison syndrome. ( 26209566 )
2015
7
Zollinger-Ellison syndrome: Revelation of the gastrinoma triangle. ( 27408649 )
2015
8
Weight Gain in Zollinger-Ellison Syndrome After Acid Suppression. ( 26164604 )
2015
9
Metastatic gastrinoma in a pediatric patient with zollinger-ellison syndrome. ( 23426004 )
2014
10
Severe symptomatic hypomagnesaemia induced by the chronic use of proton pump inhibitors: a case report of a patient with Zollinger-Ellison syndrome. ( 24635401 )
2014
11
Zollinger-ellison syndrome: classical considerations and current controversies. ( 24319020 )
2014
12
From hypomagnesaemia to Zollinger-Ellison syndrome: an adverse effect of a proton pump inhibitor. ( 25274557 )
2014
13
Missed opportunity in Zollinger-Ellison syndrome research. ( 23270867 )
2013
14
Zollinger-Ellison syndrome: recent advances and controversies. ( 24100728 )
2013
15
Current management of the Zollinger-Ellison syndrome. ( 24298844 )
2013
16
Pharmacotherapy of Zollinger-Ellison syndrome. ( 23363383 )
2013
17
Hypochlorhydria and achlorhydria are associated with false-positive secretin stimulation testing for Zollinger-Ellison syndrome. ( 23851430 )
2013
18
Secretin stimulation test for gastrin release in Zollinger-Ellison syndrome: to do or not to do? ( 23851427 )
2013
19
An unusual presentation of zollinger-ellison syndrome. ( 23466991 )
2013
20
A case of Zollinger-Ellison syndrome diagnosed by duodenal ulcer perforation into the gallbladder. ( 23357498 )
2013
21
Zollinger-Ellison syndrome. ( 24641468 )
2013
22
Current management of the zollinger-ellison syndrome. ( 25293453 )
2013
23
Multiple gastrinomas of the duodenum in a patient with sporadic Zollinger-Ellison syndrome. ( 23613167 )
2013
24
A case of Zollinger-Ellison syndrome in multiple endocrine neoplasia type 1 with urolithiasis as the initial presentation. ( 23877214 )
2013
25
Value of surgery in patients with negative imaging and sporadic Zollinger-Ellison syndrome. ( 22868363 )
2012
26
Primary hepatic gastrinoma causing zollinger-ellison syndrome: a rare and challenging diagnosis. ( 24213231 )
2012
27
Primary hepatic gastrinoma as an unusual manifestation of zollinger-ellison syndrome. ( 23271988 )
2012
28
Diagnosis of Zollinger-Ellison syndrome: increasingly difficult. ( 23112541 )
2012
29
Abdominal pain and liver lesions in Zollinger-Ellison syndrome. ( 21760542 )
2012
30
Importance of surveillance for multiple endocrine neoplasia-1 and surgery in patients with sporadic Zollinger-Ellison syndrome. ( 22902777 )
2012
31
The Zollinger-Ellison syndrome: dangers and consequences of interrupting antisecretory treatment. ( 21871248 )
2012
32
Presentation, response to lansoprazole therapy, and outcome of Zollinger-Ellison syndrome-like gastric acid hypersecretors. ( 21073392 )
2011
33
Long-term follow-up of a child with primary lymph node gastrinoma and Zollinger-Ellison syndrome. ( 21616263 )
2011
34
Zollinger-Ellison syndrome: still a diagnostic challenge in the 21st century? ( 21443889 )
2011
35
Zollinger-Ellison syndrome: presentation, response to therapy, and outcome. ( 21193359 )
2011
36
The Zollinger-Ellison syndrome and mismeasurement of gastrin. ( 21315717 )
2011
37
A 41-Year-Old Man with Two Types of Metachronous Peptic Ulcer Complication due to Zollinger-Ellison Syndrome-Regression of Pancreatic Primary after Chemoembolization of Hepatic Metastases: A Case Report. ( 21811506 )
2011
38
Zollinger-Ellison syndrome associated with a history of alcohol abuse: coincidence or consequence? ( 22136832 )
2011
39
Primary hepatic gastrinoma: an unusual case of zollinger-ellison syndrome. ( 20567542 )
2010
40
Primary hepatic gastrinoma: an unusual case of zollinger-ellison syndrome. ( 20567543 )
2010
41
[Zollinger-Ellison syndrome: a case report.]. ( 20423792 )
2010
42
Diagnosis and treatment of Zollinger Ellison syndrome in a morbidly obese patient after Roux-en-Y gastric bypass. ( 21111383 )
2010
43
Zollinger-ellison syndrome with subsequent association of insulinoma. ( 20818125 )
2010
44
Pancreatic islet cell carcinoma presenting with concurrent Cushing's and Zollinger-Ellison syndromes: case series and literature review. ( 19770666 )
2010
45
Prospective evaluation of quality of life in patients with Zollinger-Ellison syndrome. ( 20824501 )
2010
46
Reoperative surgery for the Zollinger-Ellison syndrome. ( 20919530 )
2010
47
Diagnostic efficacy of the secretin stimulation test for the Zollinger-Ellison syndrome: an intra-individual comparison using different dosages in patients and controls. ( 20299818 )
2010
48
Primary liver carcinoid tumour with a Zollinger Ellison syndrome - an unusual diagnosis: a case report. ( 19918579 )
2009
49
Gastric masses in multiple endocrine neoplasia type I-associated Zollinger-Ellison syndrome. ( 19723598 )
2009
50
Surgical management of Zollinger-Ellison syndrome; state of the art. ( 19836486 )
2009

Variations for Zollinger-Ellison Syndrome

Expression for Zollinger-Ellison Syndrome

Search GEO for disease gene expression data for Zollinger-Ellison Syndrome.

Pathways for Zollinger-Ellison Syndrome

GO Terms for Zollinger-Ellison Syndrome

Cellular components related to Zollinger-Ellison Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.35 CHGA GAST GRP SCT SST
2 extracellular region GO:0005576 9.1 CHGA GAST GRP NTS SCT SST

Biological processes related to Zollinger-Ellison Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 positive regulation of phospholipase C-activating G-protein coupled receptor signaling pathway GO:1900738 8.62 CHGA GRP

Molecular functions related to Zollinger-Ellison Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 neuropeptide hormone activity GO:0005184 8.96 GRP NTS
2 hormone activity GO:0005179 8.8 GAST SCT SST

Sources for Zollinger-Ellison Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....